A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy

Abstract

The SIRI can be used to predict the survival of patients with pancreatic adenocarcinomas who receive chemotherapy, potentially allowing clinicians to improve treatment outcomes by identifying candidates for aggressive therapy. Cancer 2016;122:2158-67. © 2016 American Cancer Society.